2022
Association Between Sugar-Sweetened Beverage Intake and Liver Cancer Risk in the Women’s Health Initiative
Zhao L, Coday M, Garcia D, Li X, Lopez-Pentecost M, Manson J, McGlynn K, Mossavar-Rahmani Y, Naughton M, Saquib N, Sesso H, Shadyab A, Simon M, Snetselaar L, Tabung F, Tinker L, Tobias D, VoPham T, Zhang X. Association Between Sugar-Sweetened Beverage Intake and Liver Cancer Risk in the Women’s Health Initiative. Current Developments In Nutrition 2022, 6: 259. PMCID: PMC9193518, DOI: 10.1093/cdn/nzac052.026.Peer-Reviewed Original ResearchSugar-sweetened beverage intakeSugar-sweetened beveragesRisk of liver cancerHigher SSB intakeHistory of diabetesSSB intakeIntake of sugar-sweetened beveragesNon-statistically significant positive associationWomen's Health Initiative Observational StudyFruit drinksHazard ratioIncident liver cancerSoft drinksConfidence intervalsMultivariable hazard ratiosLiver cancer riskWomen's Health InitiativeFood frequency questionnaireRisk factorsModifiable risk factorsSelf-administered questionnaireMedical record reviewNon-steroidal anti-inflammatory drug useCox proportional hazards regression modelsProportional hazards regression models
2021
The Effects of Chemotherapy on Circulating Plasma Carotenoids and Fat-Soluble Vitamins in Breast Cancer Patients
Bennouna D, Orchard T, Lustberg M, Kopec R. The Effects of Chemotherapy on Circulating Plasma Carotenoids and Fat-Soluble Vitamins in Breast Cancer Patients. Current Developments In Nutrition 2021, 5: 70. PMCID: PMC8180829, DOI: 10.1093/cdn/nzab034_004.Peer-Reviewed Original ResearchFat-soluble vitaminsNSAID useMultivitamin useNon-steroidal anti-inflammatory drug useAnti-inflammatory drug useNeo-adjuvant chemotherapyBreast cancer patientsPro-inflammatory cytokinesEffect of chemotherapyFat-soluble vitamin concentrationsBreast cancer chemotherapyMethods Serum samplesFree-living patientsChemotherapy commencementSerum luteinSerum retinolCancer patientsSerum concentrationsChemotherapy treatmentInflammatory processBreast cancerMerit further investigationChemotherapyPlasma carotenoidsDrug use
2020
Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry
Gianfrancesco M, Hyrich K, Al-Adely S, Carmona L, Danila M, Gossec L, Izadi Z, Jacobsohn L, Katz P, Lawson-Tovey S, Mateus E, Rush S, Schmajuk G, Simard J, Strangfeld A, Trupin L, Wysham K, Bhana S, Costello W, Grainger R, Hausmann J, Liew J, Sirotich E, Sufka P, Wallace Z, Yazdany J, Machado P, Robinson P. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Annals Of The Rheumatic Diseases 2020, 79: 859-866. PMID: 32471903, PMCID: PMC7299648, DOI: 10.1136/annrheumdis-2020-217871.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAnti-Inflammatory Agents, Non-SteroidalAntimalarialsAntirheumatic AgentsArthritis, PsoriaticArthritis, RheumatoidBetacoronavirusBiological ProductsCoronavirus InfectionsCOVID-19FemaleGlucocorticoidsHospitalizationHumansJanus Kinase InhibitorsLupus Erythematosus, SystemicMaleMiddle AgedMultivariate AnalysisPandemicsPneumonia, ViralPrednisoneProtective FactorsRegistriesRheumatic DiseasesRisk FactorsSARS-CoV-2Severity of Illness IndexSpondylarthropathiesTumor Necrosis Factor InhibitorsVasculitisYoung AdultConceptsDisease-modifying antirheumatic drugsRheumatic diseasesHospitalisation statusHigher oddsNon-steroidal anti-inflammatory drug useConventional disease-modifying antirheumatic drugsAnti-inflammatory drug useOdds of hospitalisationRheumatic disease diagnosisRheumatic disease medicationsMultivariable-adjusted modelsMultivariable logistic regressionJanus kinase inhibitorCOVID-19 outcomesCOVID-19Prednisone doseAntirheumatic drugsGlucocorticoid exposureInhibitor useAntimalarial useClinical factorsCase seriesSmoking statusReduced oddsDecreased odds
2008
Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression
Figueroa JD, Terry MB, Gammon MD, Vaughan TL, Risch HA, Zhang FF, Kleiner DE, Bennett WP, Howe CL, Dubrow R, Mayne ST, Fraumeni JF, Chow WH. Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression. Cancer Causes & Control 2008, 20: 361-368. PMID: 18989634, PMCID: PMC2726999, DOI: 10.1007/s10552-008-9250-6.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAnti-Inflammatory Agents, Non-SteroidalBody Mass IndexCarcinoma, Squamous CellCardiaCase-Control StudiesConfidence IntervalsEsophageal NeoplasmsGastroesophageal RefluxHumansImmunohistochemistryLogistic ModelsMiddle AgedMulticenter Studies as TopicOdds RatioPopulation SurveillanceRisk FactorsSmokingStomach NeoplasmsTumor Suppressor Protein p53United StatesConceptsBody mass indexNon-steroidal anti-inflammatory drugsGastroesophageal reflux diseaseRisk factorsP53 overexpressionGastric cancerCigarette smokingReflux diseaseMass indexNon-steroidal anti-inflammatory drug useTumor subtypesPopulation-based case-control studyAnti-inflammatory drug useNon-cardia gastric adenocarcinomaGastro-esophageal reflux diseaseLarger body mass indexNon-cardia gastric cancerEsophageal squamous cell carcinomaTumor p53 overexpressionRisk factor profileSquamous cell carcinomaRisk of subtypesCase-control studyAnti-inflammatory drugsP53 protein overexpression
2007
Inflammation and outcome after general thoracic surgery
Amar D, Zhang H, Park B, Heerdt PM, Fleisher M, Thaler HT. Inflammation and outcome after general thoracic surgery. European Journal Of Cardio-Thoracic Surgery 2007, 32: 431-434. PMID: 17643996, DOI: 10.1016/j.ejcts.2007.06.017.Peer-Reviewed Original ResearchConceptsC-reactive proteinMajor postoperative complicationsPostoperative complicationsIL-6Non-steroidal anti-inflammatory drug useHigh-sensitivity C-reactive proteinAnti-inflammatory drug usePreoperative C-reactive proteinSensitivity C-reactive proteinImportant postoperative complicationPreoperative albumin levelTertiary cancer centerMarkers of inflammationMarkers of outcomePostanesthesia care unitProspective data collectionGeneral thoracic surgeryLung resectionSystemic inflammationAlbumin levelsConsecutive patientsLow albuminCare unitPoor outcomeCancer Center
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply